Flecainide- NTID [Design Issues]

posted by dr.who – Macedonia, 2018-06-27 22:27 (1133 d 03:03 ago) – Posting: # 18983
Views: 3,208

Nice to meet you all since it is my first time writing on the forum.

My question is related to Flecainide. In the available literature data it is stated that flecainide is a NTID. As per the EU Guideline for BE in the case of NTID the limits are tightened, but no available PAR present a BE for flecainide with tightened limits. Also except Canada no other region have a specific list for NTIDs and for EU it is stated that is evaluated on case by case. What is your experience in design a BE of Flecainide, should the recommendation for NTID design be followed or a standard BE study design is acceptable.

Thanks.

Complete thread:

Activity
 Admin contact
21,606 posts in 4,517 threads, 1,532 registered users;
online 7 (0 registered, 7 guests [including 4 identified bots]).
Forum time: Wednesday 01:30 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5